Introduction
The gold standard for elucidating the pathogenic mechanism of a novel splicing mutation is the mutual confirmation of in silico prediction and in vitro validation. In a recent study of a large four-generation family with Spinocerebellar Ataxia (SCA), the RDDC bioinformatics tool demonstrated its power by accurately guiding subsequent functional experiments, which achieved a perfect validation. This research not only provided new insights into the pathogenesis of SCA40 but also highlighted the value of the RDDC tool in resolving the function of intronic "Variants of Uncertain Significance" (VUS).
The Clinical Challenge: A VUS in a Critical Intronic Position
The study focused on a large family pedigree where eight patients exhibited typical progressive gait ataxia and limb tremor. Using Whole Exome Sequencing (WES), the research team identified a novel heterozygous splicing mutation in the CCDC88C gene in all affected members: c.3636-4A>G.
This variant, located in intron 20, was absent from all population databases. Although its position near the splice acceptor site was suspicious, researchers needed to answer the core questions: Is this VUS pathogenic? And if so, how does it disrupt splicing?
RDDC's Precise Prediction: From "Possible" to "Specific"
To establish a clear target before committing resources to wet-lab experiments, the team used the RDDC tool for functional prediction. The RDDC analysis provided the critical breakthrough. It didn't just flag the variant as potentially damaging; it offered a highly specific, testable hypothesis: the variant would cause the insertion of a "CAG" trinucleotide (c.3636-1_3636-3insCAG) in the abnormal splice product.
This prediction translated an abstract A>G change into a concrete molecular event—a "CAG" insertion—that could be directly verified by Sanger sequencing.
Perfect Validation by Minigene Assay
Armed with RDDC's clear prediction, the team conducted an in vitro minigene assay. They transfected HEK293T cells with the mutant plasmid and sequenced the resulting mRNA. The result was a perfect match: the cells produced the aberrant splice variant confirming the abnormal insertion of "c.3636-1_3636-3insCAG".
This experimental result perfectly validated the RDDC prediction. The in silico and in vitro evidence, taken together, confirmed that the c.3636-4A>G mutation causes SCA40 by altering CCDC88C protein structure via aberrant mRNA splicing.
Case Implications
This case strongly demonstrates that RDDC is a powerful tool for researchers facing non-coding VUS. Its greatest value lies not just in predicting if a variant has an effect, but in precisely predicting what that effect will be (e.g., a specific base insertion). This provides a clear blueprint and target for functional validation, serving as a reliable partner in bridging the gap between genotype and phenotype.
Content Source and Disclaimer
This article is a compilation and interpretation of the scientific study cited below, intended to highlight the application of RDDC bioinformatics tools. All research data and conclusions belong to the original authors and publication.
Original Article:
Wang Y, Wang C, Yin H, et al. Novel c.3636-4 A>G Mutation in the CCDC88C Plays a Causative Role in Familial Spinocerebellar Ataxia. Neuroscience Letters. 2023 Dec 10;819:137535.
Article Link: https://pubmed.ncbi.nlm.nih.gov/37899026/
